SecBot SecBot
SECBOTREPLAY Home › Report › GSK

GSK · GSK filed a routine 6-K reporting the acquisition of ADSs by multiple…

GSK plc · 6-K filed Jul 16, 2026 at 10:45 ET

At the news

NEUTRALIMPACT 1/10

6-K filed Jul 16, 2026 at 10:45 ET

GSK filed a routine 6-K reporting the acquisition of ADSs by multiple PDMRs (directors and officers) through dividend reinvestment following the July 9, 2026 dividend payment. Transactions occurred on July 10 and July 14, 2026, at prices between $51.67 and $52.74, with total aggregate value of approximately $82,000. This is a standard administrative disclosure with no material financial or strategic implications.

  • Nine PDMRs acquired ADSs via dividend reinvestment on July 10 and July 14, 2026
  • Prices ranged from $51.6696 to $52.7353 per ADS
  • Total shares acquired: approximately 2,036 ADSs
  • Total transaction value: approximately $82,000

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access